Antifungal agents in current pediatric practice
- PMID: 23616182
- DOI: 10.1007/s11908-013-0337-1
Antifungal agents in current pediatric practice
Abstract
Invasive fungal infections are an important cause of morbidity and mortality in immunocompromised children. Increases in the incidence of systemic mycoses have been observed during the last 2 decades. Treatment of invasive fungal infections has improved through a better knowledge and application of current treatment strategies and through the development of new antifungal compounds. The purpose of this review is to provide antifungal treatment recommendations for pediatric patients that can help clinicians find the most suitable treatment for each specific case.
Similar articles
-
New agents for invasive mycoses in children.Curr Opin Pediatr. 2005 Feb;17(1):78-87. doi: 10.1097/01.mop.0000150630.83442.e1. Curr Opin Pediatr. 2005. PMID: 15659969 Review.
-
Current drug therapy of systemic mycoses: a review.East Afr Med J. 1995 Jun;72(6):394-8. East Afr Med J. 1995. PMID: 7498014 Review.
-
Antifungal treatment in pediatric patients.Drug Resist Updat. 2005 Aug;8(4):235-45. doi: 10.1016/j.drup.2005.06.005. Epub 2005 Jul 27. Drug Resist Updat. 2005. PMID: 16054422 Review.
-
Current and future therapy of invasive fungal infections.Curr Clin Top Infect Dis. 1998;18:19-36. Curr Clin Top Infect Dis. 1998. PMID: 9779349 Review.
-
Clinical pharmacology of antifungal agents to overcome drug resistance in pediatric patients.Expert Opin Pharmacother. 2015 Feb;16(2):213-26. doi: 10.1517/14656566.2015.1000302. Expert Opin Pharmacother. 2015. PMID: 25579070 Review.
References
LinkOut - more resources
Full Text Sources
Other Literature Sources